Efficacy Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS

  • participants needed
  • sponsor
    Innobioscience SpA
Updated on 7 November 2020
brain atrophy


The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple Sclerosis (MS). The principal outcome is to determine the efficacy, of andrographolide in retarding the progression of brain atrophy in patients with progressive forms of MS.


1. Evaluate the clinical efficacy of andrographolide 140 mg administered orally twice a day versus a placebo in: - Delay in the disability capacity progression through the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) at 24 months compared to the baseline. - Delay in cognitive impairment by means of Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT) and depression (Beck) at 24 months compared to the baseline. - Quality of life Multiple Sclerosis Impact Scale (MSIS 29) and fatigue (Krupp) through parameters reported by the patients at at 24 months compared to the baseline. - Tolerability of andrographolide measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) at 24 months. - Delay in the decrease in brain volume measured by Magnetic Resonance (MR) at 24 months compared to the baseline. - Number and volume of new lesions or larger size in T2 by MR at 24 months compared to the baseline. - Number of new hipointense lesions in T1 or (gadolinium captive) by MR at 24 months compared to the baseline. - Delay in the retineal thinning measured by Optical Coherence Tomography (OCT) and visual field at 24 months compared to the baseline. - Safety of andrographolide at 24 months through the record of adverse effects in symptom dairy and programmed interviews. 2. Explore the pharmacokinetic of andrographolide 140 mg administered orally twice day in: - bio availability and concentration of andrographolide in the patients with treatment. - half-life, maximum concentration, clearance of andrographolide in equilibrium state. 3. Determine the immunomodulatory effects of andrographolide 140 mg administered twice a day orally on lymphocyte populations in patients through the: - Determination of Th1, Th2, Th17 and Treg lymphocyte sub-populations. - Determination of cytokines IFNgama, TNFalpha, IL2, IL17alpha and TGFbeta. Population: adult patients, men and women with progressive forms of MS. The number of patients to be selected will be 68, to randomly assign 34 patients to each group.

Condition Chronic progressive multiple sclerosis
Treatment Placebo, Andrographolides
Clinical Study IdentifierNCT02273635
SponsorInnobioscience SpA
Last Modified on7 November 2020


How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note